ABSTRACT
This study aims to investigate the trends in maternal age distribution and estimate the live birth and population prevalence of Down’s syndrome in China.
Using population survey data, we demonstrated the change of maternal age over the past three decades and its effect on the live birth prevalence of Down’s syndrome. We also integrated the live birth prevalence and the survival rate to estimate the population prevalence of Down’s syndrome. Chi-square test was used to compare the maternal age distributions across survey years.
The results show that the maternal age has been rising over the past 30 years in China at national level. The proportion of mothers aged 35 and over increased from 3.62% in 1985 to 14.40% in 2010. The estimated live birth prevalence of Down’s syndrome has mirrored the same increase of the maternal age from 1.07 per 1000 live births in 1985 to 2.36 per 1000 live births in 2010. At City level, the change of maternal age and live birth prevalence of Down’s syndrome were more significant than at Town and County levels. The proportion of mothers aged 35 and over increased from 2.17% in 1995 to about 16% in 2010 at City level, while it increased from 2.03% to 13.65% at County level. The total estimated number of people with Down’s syndrome who were still alive in 2012 and aged below 27 was 611,053, and the estimated population prevalence is 0.45 per 1000.
To conclude, this study provides a clear message about the rising trend in maternal age in both urban and rural areas in China since 1985 and its effect on the estimated birth prevalence with Down’s syndrome. The regional differences should be taken into account for planning population policy and allocating medical resources to reduce the burden of family with Down’s syndrome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is not funded.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is secondary data analysis based on National Bureau of Statistics reported numbers. No ethical approval is needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study is from National Bureau of Statistics of the People's Republic of China: http://www.stats.gov.cn/tjsj/ndsj/# and from China statistics yearbook: http://nianjian.xiaze.com/plus/download.php?open=2&id=18067&uhash=b1b488b63840640a0b40304c
http://nianjian.xiaze.com/plus/download.php?open=2&id=18067&uhash=b1b488b63840640a0b40304c
